跳至主要内容
临床试验/EUCTR2007-003736-34-HU
EUCTR2007-003736-34-HU进行中(未招募)1 期

Effect of low dose continuous treatment with Ciclesonide over one year on the time to first exacerbation in children with mild asthma versus intermittent treatment for exacerbations - POPCICLE

ycomed Canada Inc.0 个研究点目标入组 240 人开始时间: 2007年7月10日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • · Patients giving assent and parents/guardians informed consent
  • · Outpatients, male or female, age 4 to 11 years inclusive
  • · Symptoms consistent with the diagnosis of asthma for at least 12 months not requiring the use of an ICS (less or equal to 250mg/day FP or equivalent) for more than 8 weeks within the last 12 months (no ICS 30 days prior to B0)
  • · FEV1 at least 80 % of predicted, measured at least 4 hours after the inhalation of short acting b2-agonist (e.g. salbutamol), or at least 24 hours after the inhalation of a LABA (salmeterol or formoterol), anticholinergics or the oral intake of theophylline or leukotriene antagonists
  • · Ability to perform reproducible lung function tests
  • · With the exception of asthma, are in good health
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • · History of life-threatening asthma
  • · Hospitalization for asthma within the past 3 months or > or = 2 hospitalizations within the last year.
  • · Asthma exacerbation, or relevant RTI within the last 30 days requiring anti-asthmatic medication beyond an increase in bronchodilator dose
  • · Initiation of immunotherapy within 6 months of B0, or planned initiation within the study period
  • · Severe atopic dermatitis
  • · Concomitant severe diseases or diseases which are contraindicated for the use of ICS
  • · Relevant lung diseases causing alternating impairment in lung function
  • · Prematurely born children (< 36 weeks of gestation)
  • · Conditions [cardiovascular, neurological, hepatic, renal, respiratory (other than asthma or allergic rhinitis), or others] considered as clinically significant
  • · History of cataracts and/or glaucoma
  • · Suspected hypersensitivity to ICS or short-acting ß agonist
  • · Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
  • · Use of systemic corticosteriods for > 30 days within the previous year, or within 30 days (injectable depot steriods 6 weeks) of B0 or more than 3 times during the last 6 months
  • · Use of drugs not allowed or washout times of drugs cannot be adhered to
  • · Need for concomitant medications that interfere with the study
  • · Lung disease other than asthma, concomitant severe disease
  • · Pregnancy, intention to become pregnant during the trial or lack of safe contraception in females of child-bearing potential
  • · Patients who are mentally incapacitated
  • · Suspected non-compliance or inability to follow the procedures of the study
  • · Participation in another trial within 30 days of enrolment, or previous enrolment in current study
  • · Patient or parents relocation during the study, preventing adherence to visit schedule
  • · Parents or legal representative are, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained

研究者

发起方
ycomed Canada Inc.

相似试验

Effect of low dose continuous treatment with... | 临床试验